Page last updated: 2024-11-02

pioglitazone and Cholangiocellular Carcinoma

pioglitazone has been researched along with Cholangiocellular Carcinoma in 3 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"To explore the effect and mechanism of ligand pioglitazone (PGZ) activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro."7.74[Effect of ligand pioglitazone activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro and the expression regulation of related genes]. ( Cao, GQ; Chen, QY; Cheng, NS; Li, M; Wu, LH; Xiong, XZ; Zhang, FQ, 2007)
"Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat."5.34Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma. ( Hashizume, K; Hosoda, W; Mori, J; Sato, A; Suzuki, S; Yamazaki, M, 2007)
"To explore the effect and mechanism of ligand pioglitazone (PGZ) activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro."3.74[Effect of ligand pioglitazone activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro and the expression regulation of related genes]. ( Cao, GQ; Chen, QY; Cheng, NS; Li, M; Wu, LH; Xiong, XZ; Zhang, FQ, 2007)
"Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat."1.34Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma. ( Hashizume, K; Hosoda, W; Mori, J; Sato, A; Suzuki, S; Yamazaki, M, 2007)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kobuke, T1
Tazuma, S1
Hyogo, H1
Chayama, K1
Li, M1
Cheng, NS1
Xiong, XZ1
Wu, LH1
Chen, QY1
Zhang, FQ1
Cao, GQ1
Suzuki, S1
Mori, J1
Yamazaki, M1
Sato, A1
Hosoda, W1
Hashizume, K1

Other Studies

3 other studies available for pioglitazone and Cholangiocellular Carcinoma

ArticleYear
A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspase 3; Caspase

2006
[Effect of ligand pioglitazone activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro and the expression regulation of related genes].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2007, Volume: 38, Issue:3

    Topics: Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Dose-Response Relationship, Drug; Gene Expressi

2007
Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:20

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diabetes Mellitus, Type 2;

2007